Naturally Immune For Life

Selective IgA Deficiency (SIgAD) is the most common primary immunodeficiency. It is characterized by very low or undetectable levels of Immunoglobulin A (IgA) in the blood and mucosal secretions. Although many individuals with SIgAD have no symptoms, others experience recurrent respiratory and gastrointestinal infections, autoimmune diseases such as celiac disease and rheumatoid arthritis, or allergic conditions including asthma, eczema, and food allergies. These observations highlight the critical role that IgA plays in maintaining healthy mucosal immunity throughout the body.

In mammals, mothers provide passive immune protection by delivering Secretory Immunoglobulin A (SIgA) through colostrum and breast milk. Unlike antibodies that circulate in the bloodstream, SIgA is specifically designed to protect mucosal surfaces, including the gastrointestinal and respiratory tracts, where infants first encounter bacteria, viruses, toxins, and food antigens.

The production and transfer of SIgA is a highly coordinated biological process. As the mother’s immune system encounters microorganisms in her environment, specialized immune cells within the intestinal and other mucosal tissues become activated. These cells migrate to the mammary glands, where they produce dimeric IgA, a form consisting of two IgA molecules joined together. The dimeric IgA then binds to the Polymeric Immunoglobulin Receptor (pIgR) located on mammary epithelial cells. The receptor transports the antibody across the cell and into breast milk through a process known as transcytosis.

During this journey, part of the receptor remains attached to the antibody, forming the Secretory Component. This additional protein transforms IgA into Secretory IgA (SIgA), protecting it from degradation by stomach acid and digestive enzymes after it is consumed by the infant. As a result, SIgA survives passage through the digestive tract and reaches the intestine largely intact, where it can perform its protective functions.

Rather than killing microorganisms directly, SIgA works by coating bacteria, viruses, and toxins, preventing them from attaching to the intestinal lining. This process, known as immune exclusion, allows potentially harmful microbes to be removed naturally while minimizing unnecessary inflammation. At the same time, SIgA helps guide the development of a healthy gut microbiome by promoting beneficial bacteria and limiting the overgrowth of potentially harmful species. Through these combined actions, maternal SIgA provides newborns with a sophisticated form of immune protection while their own immune system gradually matures.

One of the most promising discoveries in recent years is the recognition that the gut microbiome itself plays an important role in regulating SIgA production. Rather than acting independently, beneficial bacteria continuously communicate with immune cells located within the intestinal wall. Their metabolic byproducts, particularly short-chain fatty acids such as acetate, stimulate immune signaling pathways that encourage B cells to mature into plasma cells capable of producing IgA. This creates a positive feedback loop in which beneficial microbes help strengthen the very immune barrier that supports their survival.

Among these beneficial organisms, Bifidobacterium longum subsp. infantis has received considerable attention because of its close relationship with human milk oligosaccharides (HMOs). During infancy, HMOs selectively nourish B. infantis, allowing it to dominate the intestinal microbiome while supporting healthy immune development. Researchers now believe that many of these same biological pathways remain active in adults, even though the mature microbiome is more stable and resistant to change.

Clinical studies have demonstrated that several commercial strains of B. infantis can increase or help maintain intestinal SIgA through different mechanisms. Some strains directly increase fecal SIgA concentrations, while others reduce intestinal inflammation, promote regulatory T cells, improve epithelial barrier integrity, or increase production of short-chain fatty acids that indirectly stimulate IgA secretion. Although the strength of evidence varies among strains, the overall findings consistently point toward improved mucosal immune function rather than simply altering bacterial composition.